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Currently, there are gaps in the allergic rhinitis (AR)
guidelines (and the evidence upon which they are based)
that impede their function. Firstly, there is a scarcity of
high quality evidence supporting AR treatment decisions
[1]. Randomized controlled trials (RCTs) often fail to com-
pare active treatments and use endpoints that are regula-
tory (not patient) driven. Secondly, a common AR control
language for both patients and physicians and a common
concept of AR control is missing. Finally, to date, the
guidelines do not draw on evidence from real-life studies.
These are important as they determine the effects of treat-
ment under the usual conditions of care, thus maximizing
applicability of findings to everyday practice. Many of
these gaps are currently being filled. Firstly, the efficacy
and safety of MP29-02* (a novel intranasal formulation of
azelastine hydrochloride and fluticasone propionate in an
advanced delivery system) has been shown versus active
comparators in large, good quality, RCTs [2,3]. MP29-
02*’s superiority over currently considered gold standard
therapy (INS) was assessed using more clinically-relevant
efficacy endpoints, defining treatment response in a way
that is understandable and relevant to patients and health
care providers, helping to explain why current first-line
therapy often provides sub-optimal symptom relief. Sec-
ondly, a simple visual analog scale (VAS) has recently
been proposed by MACVIA-LR ARIA as the control lan-
guage of AR. This will form the basis for the new AR
guidelines as part of an integrated care pathway (ICP) [4].
This VAS is also an integral component of a new app
called Allergy Diary, designed to assess and track disease
control. AR control has been categorized using VAS cut-
off scores as ‘well-, partly- and un-controlled’. Finally, real-
life studies are slowly gaining acceptance. One such study
recently showed effective and rapid symptom control by
MP29-02* in AR patients in real-life, using the same VAS
score advocated in the ICP. Filling these gaps will ensure
that treatment decisions are clinically relevant, encourage
simplification of and compliance with AR management
guidelines, ensure open and effective communication
between all stakeholders and facilitate tailoring of AR
medication to patients’ needs.
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